HOME >> BIOLOGY >> NEWS
Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation

BARCELONA, Spain, 15 June 2007 Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE (infliximab) over two years experienced significant improvement in spinal mobility. In addition, REMICADE-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging (MRI).

The recommended dose of REMICADE in AS is 5 mg/kg given as an IV induction regimen at 0, 2 and 6 weeks followed by a 5 mg/kg maintenance regimen every 6 weeks in the United States or every 6-8 weeks in the European Union. AS is a progressive rheumatic disease that leads to inflammation of the back, resulting in pain, stiffness and reduced mobility, which in advanced cases can result in fusion of the vertebrae of the spine ('ankylosis'). Data collected from 279 patients with AS as part of the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) trial were analyzed to determine the long-term effect of REMICADE on spinal mobility. The double-blind extension of this 24-week placebo-controlled study utilized the Bath Ankylosing Spondylitis Metrology Index (BASMI) and chest expansion measurements to assess range of motion in patients with AS.

Patients in ASSERT were treated and assessed at six week intervals through week 102. According to the findings, compared with placebo group (N=78), at week 24 the REMICADE-treated patients (N=201) had a greater improvement in BASMI (defined as a change of at least 1 in the BASMI score) scores (-0.7 vs. -0.2, respectively; P = 0.02), and in percent change in chest expansion (44 percent vs. 19 percent, respectively, P = 0.03). Fifty-one percent of REMICADE-treated patients vs. 31 percent of placebo-treated patients achieved a clinically meaningful improvement in BASMI (P < 0.01). The improvement seen at week 24 was main
'"/>

Contact: Brian Kenney
bkenney1@cntus.jnj.com
215-325-2107
Centocor, Inc.
15-Jun-2007


Page: 1 2

Related biology news :

1. Long-term ulcerative colitis study shows Remicade responders maintained improvement
2. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
3. Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis
4. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
5. Biocontrol of invasive water hyacinth contributes to socioeconomic and health improvements in Africa
6. Kansas, Missouri School Board members to explore improvements in science-related education
7. Gene therapy study shows safety and statistically significant improvement in Parkinsons disease
8. New study suggests special cocoa may lead to sustained improvement in blood vessel function
9. Eculizumab is well-tolerated and shows significant improvement in PNH patients (Ph III)
10. Research could lead to dramatic improvement in scanning for serious diseases
11. Do green markets actually lead to improvements in environmental quality?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced ... the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department ... scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... and innovation in technology and compliance, announces a new solution to manage regulated ... ensure every layer of their technology stack complies with FDA and global regulations. ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: